Hormonal
GLP-1 receptor agonists (GLP-1RAs) promote sustained weight loss in adults with obesity or type 2 diabetes primarily by increasing energy expenditure and reducing food intake via central nervous system satiety signaling, independent of glycaemic control.
If you have obesity or Type 2 Diabetes, GLP-1 medications like semaglutide or liraglutide are proven to help you lose significant weight (around 15% in trials) by reducing hunger and increasing energy burn. They are taken as a weekly or daily injection, often alongside diet and exercise changes. These are not quick fixes but chronic treatments that mimic a natural gut hormone to help regulate your body's weight set-point.
pharmacokinetic investigation in human participants suggested the effects of liraglutide on weight loss are primarily mediated through increased energy expenditure (66). ... GLP-1 crosses the blood-brain barrier to agonise GLP-1R within hypothalamic CNS centres, where ingestive behaviour and satiety is dictated [(117); Figure 3]. Increased satiety reduces food intake, with resultant weight loss being an important benefit in overweight or obese-T2DM patients.
Why this rating
The paper cites multiple large-scale Phase III clinical trials (SCALE, SUSTAIN) and long-term prospective outcomes, indicating high-quality clinical evidence.
Source
Proglucagon-Derived Peptides as Therapeutics
Ryan A. Lafferty et al. · Frontiers in Endocrinology · 2021
DOI 10.3389/fendo.2021.689678
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →